GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Seelos Therapeutics
Seelos is a biopharmaceutical company focused on diseases of the central nervous system. Its stock price is highly speculative and driven by news of clinical trials of its drugs, including those involving psychedelics.
Share prices of companies in the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company developing drugs to treat central nervous system disorders, including depression and suicidal behavior. We've categorized it as a Pharma: Psycho. The chart below shows how investors view the mental health sector.
Broad Market Index - GURU.Markets
Seelos Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, including depression and suicidal behavior. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Seelos' performance.
Change in the price of a company, segment, and market as a whole per day
SEEL - Daily change in the company's share price Seelos Therapeutics
Seelos Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies working with psychedelics. This metric is a measure of sensitivity to clinical trial news.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on drugs for the treatment of central nervous system disorders, including psychedelics. This is a highly speculative sector. The chart below illustrates the high volatility typical of this niche, reflecting its risks and potential.
Daily change in the price of a broad market stock, index - GURU.Markets
Seelos Therapeutics is a biotech company developing psychedelic-based drugs. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Seelos Therapeutics
Seelos Therapeutics' year-over-year performance tells the story of its diversified, yet high-risk, portfolio of CNS developments. Its 12-month market cap depends entirely on clinical trial data from its drugs for depression, ALS, and other serious conditions. Success in any of these programs could be a breakthrough.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Seelos, a late-stage biotech company, develops drugs for the treatment of central nervous system diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Seelos Therapeutics is a biotech whose value is locked into its pipeline of CNS drugs. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Seelos Therapeutics
Seelos is a biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its diverse pipeline of drugs is its primary driver.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders and rare diseases, including psychedelic-based therapies. The chart below shows the overall dynamics of the psychedelic pharmaceutical sector, which is gaining attention as a potential breakthrough in the treatment of mental disorders.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Seelos Therapeutics is a biotech company developing drugs to treat diseases of the central nervous system. Its shares live in the world of clinical trials. Positive data can trigger explosive growth, while failures can cause a collapse, and these events are in no way related to the overall state of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Seelos Therapeutics
The weekly performance of Seelos, a biopharmaceutical company, reflects the search for drugs to treat central nervous system disorders. Share prices are responding to clinical trial data for their drugs, including those based on psychedelics.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Seelos Therapeutics focuses on developing drugs to treat central nervous system disorders, including suicidal behavior and rare diseases. The chart will help separate its own news-driven dynamics from the overall fluctuations in the neuroscience sector, highlighting its place in the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Seelos Therapeutics is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does Seelos live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
SEEL - Market capitalization of the company Seelos Therapeutics
Seelos's market capitalization tells the story of a biotech company focused on diseases of the central nervous system. Its volatile chart reflects the company's development of drugs to treat complex conditions like depression and suicidal ideation. Its performance reflects investor assessments of data from its numerous clinical programs.
SEEL - Share of the company's market capitalization Seelos Therapeutics within the market segment - Pharma psycho
Seelos Therapeutics is a biotech company focused on diseases of the central nervous system. Its small share of the sector's market capitalization reflects the early stage and high risk nature of its developments. The chart reflects investor hopes for a breakthrough in the treatment of complex mental disorders.
Market capitalization of the market segment - Pharma psycho
Seelos Therapeutics is a clinical-stage biotech company focused on diseases of the central nervous system, including suicidal behavior and psychedelics. The chart below shows the market capitalization of this sector. Its dynamics reflect the enormous need for new approaches to treating mental disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
Seelos Therapeutics is a biotech company focused on diseases of the central nervous system, including depression and suicidal tendencies. Its market cap reflects the hope for a breakthrough in the treatment of the most complex mental health conditions. Its volatility reflects the enormous social importance and scientific challenges of this field.
Book value capitalization of the company, segment and market as a whole
SEEL - Book value capitalization of the company Seelos Therapeutics
Seelos Therapeutics' balance sheet represents its capital invested in developing drugs for the treatment of central nervous system disorders, including suicidal tendencies and rare diseases. This provides a real, scientific foundation for solving the most complex problems in psychiatry and neurology. How has this risky biotech asset changed? The chart below shows its dynamics.
SEEL - Share of the company's book capitalization Seelos Therapeutics within the market segment - Pharma psycho
Seelos Therapeutics develops drugs for the treatment of central nervous system disorders, including psychedelics. The chart shows the share of its R&D assets, reflecting the physical foundation of its research in this complex and promising field.
Market segment balance sheet capitalization - Pharma psycho
Seelos, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg graph for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Seelos's book value is its pipeline of drugs for treating central nervous system disorders, including suicidal depression and Parkinson's disease. The company's assets are its intellectual property. The chart below shows how this biotech compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Seelos Therapeutics
Seelos Therapeutics is developing drugs to treat diseases of the central nervous system. Its balance sheet is based on R&D expenses. Its market capitalization is the pure hope of investors for the success of its clinical trials. The MvsBCap_Co chart shows the volatile path from a scientific idea to a potential drug in the eyes of the market.
Market to book capitalization ratio in a market segment - Pharma psycho
Seelos Therapeutics is a biotech company developing drugs for the treatment of central nervous system disorders, including depression and suicidal tendencies. Its valuation on the chart is speculative and depends on the success of its risky clinical programs.
Market to book capitalization ratio for the market as a whole
Seelos Therapeutics is a biopharmaceutical company focused on neuroscience and psychiatry. Its market valuation is a bet on the future success of its drugs. This chart helps assess how high the biotech risk and potential premium is compared to the market average.
Debts of the company, segment and market as a whole
SEEL - Company debts Seelos Therapeutics
Seelos Therapeutics, a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, uses capital to fund its risky but potentially breakthrough research. This chart shows how the company raises funds to advance its programs in challenging areas such as depression and Parkinson's disease.
Market segment debts - Pharma psycho
Seelos Therapeutics is a clinical-stage biotech focused on diseases of the central nervous system. This chart shows that the company, like its peers, funds its expensive and risky research exclusively with equity, avoiding the burden of debt until potential success.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system, including psychedelics for the treatment of depression. This is a risky area. This chart shows the company's reliance on debt to fund its clinical trials, which is a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression and Parkinson's disease. The chart shows how aggressively the sector uses debt for R&D, providing context for how Seelos finances its risky but potentially important programs.
Debt to book value of all companies in the market
Seelos Therapeutics, a biopharmaceutical company focused on diseases of the central nervous system, conducts expensive and risky clinical trials. This chart, reflecting the overall debt burden in the market, provides context. It helps us understand how typical its financial strategy is for biotech, where the path from idea to product requires enormous capital.
P/E of the company, segment and market as a whole
P/E - Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression and Parkinson's disease. This chart shows how investors value its pipeline. This value is dependent on clinical trial results.
P/E of the market segment - Pharma psycho
Seelos's focus on treating CNS diseases is a high-risk area. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Seelos, with its diverse portfolio of drugs for depression and other disorders, is valued as a portfolio of risky but potentially highly valuable scientific ideas.
P/E of the market as a whole
Seelos Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its valuation depends entirely on the success of its drugs in clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. Seelos's fate is decided in the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Seelos Therapeutics
This chart for Seelos Therapeutics, Inc., a biopharmaceutical company focused on diseases of the central nervous system, shows market expectations for its clinical development. It reflects investor confidence in the potential of its drugs to treat suicidal ideation, depression, and rare diseases.
%20P%2FE%20Seelos%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Seelos-Therapeutics&v=1772636875332 "Chart of the company's future (projected) P/E Seelos Therapeutics")
Future (projected) P/E of the market segment - Pharma psycho
Seelos Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. This chart shows industry forecasts, helping to assess how the market views Seelos's risky but potentially valuable pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772636875333 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Seelos Therapeutics, Inc. is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, including psychedelics. This is a risky area. This chart shows how ready the market is for such revolutionary, yet highly controversial and risky, medical investments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636875346 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system, including suicidal behavior and rare diseases. While in the clinical stage, it is losing money. This chart illustrates the financial risks and potential social impact of psychiatric drug development.
Profit of companies in the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression and suicidal behavior. This graph, which shows sector profitability, demonstrates the tremendous demand for new treatments for mental disorders. Their research using ketamine may offer hope to many patients.
Overall market profit
Seelos Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system, including depression and Parkinson's disease. Its pipeline includes several candidates at various stages of development. Success depends on research results. This total return chart reflects the investment climate, which is important for funding such projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and neurological disorders. This chart summarizes analyst opinions on the likelihood of success of its clinical programs in these complex but potentially large markets.
%20profit%20of%20the%20company%20Seelos%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Seelos-Therapeutics&v=1772636875391 "Graph of future (projected) profit of the company Seelos Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma psycho
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and suicidal tendencies. The company's future depends on the success of clinical trials. This timeline for the biotech sector reflects the general expectations for innovation in mental health.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772636875396 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Seelos Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. Its future is determined by the success of clinical trials. The overall economic outlook, reflected in this chart, impacts the investment climate and the availability of capital to continue expensive development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636875413 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company developing drugs to treat central nervous system disorders, including depression and Parkinson's disease. For a clinical-stage company, this chart is key. It shows how investors view its pipeline and future sales potential.
P/S market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression and suicidal tendencies. The company's valuation is based on the future potential of its developments. This chart helps understand how investors value Seelos's mental health portfolio.
P/S of the market as a whole
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. This chart, which reflects market revenue estimates, serves as a benchmark for Seelos's hopes. It demonstrates the value investors place on the company's pipeline.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Seelos Therapeutics
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders and rare diseases. This chart reflects investor expectations that its diversified pipeline of candidates will successfully complete clinical trials and reach the market.
%20P%2FS%20Seelos%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Seelos-Therapeutics&v=1772636875451 "The graph of the company's future (projected) P/S Seelos Therapeutics")
Future (projected) P/S of the market segment - Pharma psycho
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders, including depression and suicidal ideation. This chart reflects average revenue expectations in the biotech sector, providing insight into the market's perception of Seelos' potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772636875457 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression and Parkinson's disease. This indicator reflects collective market expectations. The company's success in developing new treatments for these complex conditions fuels investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636875482 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Seelos Therapeutics
This chart shows the revenue of Seelos Therapeutics, a clinical-stage biopharmaceutical company focused on central nervous system diseases and psychedelics. Its revenue, if any, is generated through partnerships, reflecting research progress rather than commercial sales of finished products.
Sales of companies in the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and neurological disorders. This chart shows the growth of the CNS therapeutics market. The company's portfolio is aimed at developing breakthrough treatments, including those using psychedelic compounds.
Overall market sales
Seelos Therapeutics is a biopharmaceutical company specializing in diseases of the central nervous system. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to finance risky projects in the field of psychopharmacology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Seelos Therapeutics
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. Future revenue depends on the success of clinical trials. The chart reflects analysts' confidence in its R&D.
%20sales%20of%20the%20company%20Seelos%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Seelos-Therapeutics&v=1772636875541 "Schedule of future (projected) sales of the company Seelos Therapeutics")
Future (projected) sales of companies in the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, including depression, suicidal ideation, and rare neurological disorders. This chart shows the forecast for the entire psychopharmacology market, where Seelos is working to develop breakthrough treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772636875556 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Seelos Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders and rare diseases. This chart, reflecting investor sentiment, impacts the availability of capital for funding long and risky clinical trials in neurology and psychiatry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636875579 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Seelos Therapeutics
Seelos Therapeutics is a biotech company developing drugs to treat central nervous system disorders, including suicidal tendencies and rare diseases. Being in the clinical stage, it incurs significant expenses. This chart shows its net losses—investments in developing drugs for the most complex and socially significant neurological conditions.
Market segment marginality - Pharma psycho
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of potential for patients.
Market marginality as a whole
Seelos Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. Their portfolio also includes psychedelic compounds. This overall profitability curve is irrelevant to them. Their future depends solely on the results of their clinical programs.
Employees in the company, segment and market as a whole
Number of employees in the company Seelos Therapeutics
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system. It operates with a small team of experts. This chart reflects its lean, R&D-focused model, with many functions outsourced.
Share of the company's employees Seelos Therapeutics within the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on central nervous system treatments, including programs for depression and rare diseases. This chart reflects its share of the total number of researchers in these areas. It is an indicator of the scale of its clinical programs and the size of the scientific team working on new drug development.
Number of employees in the market segment - Pharma psycho
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, including depression and suicidal behavior. This chart shows employment trends in the mental health sector. The growing number of scientists here reflects the urgent need for new, fast-acting treatments.
Number of employees in the market as a whole
Seelos Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. Its future depends on the success of clinical trials and raising capital. The overall economic environment, reflected in this chart, influences investor willingness to fund long-term, high-risk research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Seelos Therapeutics (SEEL)
Seelos Therapeutics is a biotech company focused on drugs for the treatment of central nervous system disorders, including depression and Parkinson's disease. It is a clinical-stage R&D company. The chart shows that the company's market value is a valuation of its development pipeline. The high market capitalization per employee reflects the small team of scientists working on drugs for potentially huge markets.
%20of%20the%20company%20Seelos%20Therapeutics%20(SEEL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Seelos-Therapeutics-SEEL&v=1772636875791 "Chart of market capitalization per employee (in thousands of dollars) of the company Seelos Therapeutics (SEEL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders and rare diseases. Its value is determined by the potential of its clinical programs. This chart shows the market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772636875805 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on drugs for the treatment of central nervous system diseases. The chart shows the assessment of scientific potential. It reflects how the market values their development pipeline, where the contribution of a small team of scientists can lead to the creation of breakthrough drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636875816 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Seelos Therapeutics (SEEL)
Seelos Therapeutics is a clinical-stage biotech company specializing in diseases of the central nervous system (CNS), including the development of psychedelic-based drugs (ketamine) for the treatment of depression. This is R&D. This chart shows capital burn: the amount the company spends on each scientist.
%20Chart%20Seelos%20Therapeutics%20(SEEL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Seelos-Therapeutics-SEEL&v=1772636875843 "Company Profit Per Employee (in thousands of dollars) Chart Seelos Therapeutics (SEEL)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Seelos Therapeutics is a clinical-stage biotech company focused on diseases of the central nervous system, including the development of psychedelics (ketamine). This loss per employee reflects the high cost of conducting clinical trials in this complex field.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772636875848 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Seelos Therapeutics (SEEL) is a clinical-stage biotech company specializing in the treatment of neurological and psychiatric disorders (including suicide). It is an R&D company and is not profitable. This chart shows its capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636875851 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Seelos Therapeutics (SEEL)
Seelos Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders and rare diseases. This chart reflects the progress of its research monetization. Revenue growth at this stage will depend on the success of clinical trials and potential partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Seelos-Therapeutics-SEEL&v=1772636875856 "Sales chart per company employee Seelos Therapeutics (SEEL)")
Sales per employee in the market segment - Pharma psycho
Seelos Therapeutics (SEEL) is a biotech company focused on diseases of the central nervous system (CNS). Their pipeline includes developments related to ketamine (for depression) and Parkinson's disease. This chart shows how productive their R&D team is, measuring revenue (from partnerships) per scientist.
Sales per employee for the market as a whole
Seelos Therapeutics (SEEL) is a clinical-stage biotech company specializing in drugs for the treatment of central nervous system disorders (including suicidal behavior and psychedelics). The company has no commercial revenue yet. This chart illustrates a typical R&D situation: the entire research team is working on developing future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Seelos Therapeutics (SEEL)
Seelos Therapeutics is a biotech company developing drugs for the treatment of central nervous system disorders, including psychedelics (ketamine) for depression. The bearish sentiment shown in this chart reflects investors' bets that its speculative and risky pipeline will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Seelos-Therapeutics-SEEL&v=1772636875878 "Short Shares Chart for the Company Seelos Therapeutics (SEEL)")
Shares shorted by market segment - Pharma psycho
This chart shows investor skepticism toward the CNS drug development sector. Seelos focuses on suicidal disorders and neuroscience. This is an extremely complex area: the high short interest in the sector signals that investors don't believe clinical trials will succeed and expect failure in this high-risk industry.
Shares shorted by the overall market
Seelos is a biotech company operating in speculative territory (psychedelics, suicidal ideation). This chart shows the overall market pessimism. When market fears mount, investors are unwilling to deal with R&D risks coupled with regulatory risks. They are the first to sell off such "hype" stories.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Seelos Therapeutics (SEEL)
Seelos Therapeutics (SEEL) is a biotech company developing drugs for the treatment of central nervous system disorders, including depression (ketamine). This industry is highly speculative. This oscillator measures hype, showing overbought peaks (above 70) on positive data announcements or deep oversold troughs (below 30) in anticipation of funding.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Seelos-Therapeutics-SEEL&v=1772636875922 "RSI 14 indicator chart for the company's stock Seelos Therapeutics (SEEL)")
RSI 14 Market Segment - Pharma psycho
Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on treating CNS disorders. Their pipeline includes drugs (including ketamine-based ones) for the treatment of depression and suicidality. This chart reflects the overall sentiment in the psychopharmacology sector, helping to assess the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
Seelos (SEEL) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SEEL (Seelos Therapeutics)
Seelos Therapeutics is a biotech company focused on treating central nervous system disorders, particularly drugs (including ketamine) for depression and suicidal ideation. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on clinical trial success in this complex area.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SEEL-Seelos-Therapeutics&v=1772636875995 "A chart showing analyst consensus forecasts for the expected stock price. SEEL (Seelos Therapeutics)")
The difference between the consensus estimate and the actual stock price SEEL (Seelos Therapeutics)
Seelos (SEEL) is a high-risk biotech developing drugs (including ketamine) for the treatment of severe central nervous system diseases (depression, ALS). This chart shows how the current share price differs from its "fair" value. It reflects the "venture" valuation of analysts for this complex R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SEEL-Seelos-Therapeutics&v=1772636876037 "A chart showing the difference between the consensus forecast and the actual stock price. SEEL (Seelos Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Seelos (SEEL) is a high-risk biotech betting on psychedelics (ketamine) for depression and drugs for neurological disorders (ALS). This chart shows analysts' overall expectations for the entire psychopharma sector. It reflects whether experts believe in a "psychedelic renaissance" in medicine.
Analysts' consensus forecast for the overall market share price
Seelos Therapeutics (SEEL) is a biotech company working at the forefront of psychiatry. They are developing drugs for the treatment of depression (based on ketamine) and neurological disorders. This chart shows the overall risk appetite in the market, reflecting the willingness of investors and analysts to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Seelos Therapeutics
Seelos Therapeutics is a biotech company focused on developing treatments for central nervous system disorders, including rare diseases and mood disorders. It is a venture-backed company in the research stage. This chart is an integral indicator reflecting the market perception of the scientific potential of their developments, the risks of clinical trials, and financial stability.
AKIMA Market Segment Index - Pharma psycho
Seelos Therapeutics (SEEL) is a pharma company focused on psychotherapy and the central nervous system. They attack the most challenging targets: suicidal ideation (depression) and Parkinson's disease. This is high-risk R&D. This chart compares their composite index to the sector average, showing their position in the drug race.
The AKIM Index for the overall market
Seelos Therapeutics is a biopharmaceutical company developing treatments for central nervous system diseases and rare disorders. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story, struggling for survival, compares to overall economic trends.
